Chairman: Sylvie Gregoire, PharmD
Dr. Grégoire served as President of the Human Genetic Therapies division of Shire plc, a public biopharmaceutical company, from 2007 to 2013 and from 2005 to 2008 she served as a director of IDM Pharma, Inc., a public biotechnology company that now operates as a subsidiary of Takeda Pharmaceuticals, including serving as its Executive Chair from August 2006 to October 2007. From 2004 to 2005, Dr. Grégoire served as President, Chief Executive Officer and Executive Member of the board of directors of GlycoFi, Inc., a private biotechnology company. Prior to that, Dr. Grégoire was employed in several key operating and regulatory affairs positions at Biogen, Inc. (now known as Biogen Idec Inc.) and Merck & Co. Dr. Grégoire currently serves on the board of Novo Nordisk A/S and Galenica Limited, and within the last five years has served on the board of Cubist Pharmaceuticals, Inc. Dr. Grégoire holds a Bachelor of Science degree from Laval University and a Doctoral degree from the State University of New York at Buffalo.
Carrolee Barlow, MD, PhD
Dr. Barlow is the current CEO of The Parkinson’s Institute and Clinical Center. Dr. Barlow’s previous work has spanned clinical care, laboratory and clinical research, academia, and industry. She is the former Chief Scientific Officer and Chief Medical Officer of BrainCells, Inc. in San Diego, California, a biotechnology company focused on the discovery and development of small molecules for the treatment of neurological and psychiatric disease using human neural stem cell technology. Prior to BrainCells, she served as the Director of Molecular Neuroscience and Therapeutic Area Head for Stroke and Neurodegeneration at Merck Research Laboratories. Dr. Barlow has held a faculty position in the Laboratory of Genetics at the Salk Institute for Biological Studies in La Jolla, California. Dr. Barlow received her MD from the University of Utah, did her residency in Internal Medicine at The New York Hospital, Cornell Medical Center, and went on to obtain a PhD in molecular and developmental biology at the Karolinska Medical Nobel Institute in Stockholm, Sweden.
Arthur Tzianabos, PhD
Dr. Tzianabos is the President and Chief Scientific Officer of OvaScience. Prior to this role, he was Chief Scientific Officer at the OvaScience. Previously, he served as Senior Vice President and Head, Research and Early Development at Shire. Prior to Shire, Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.
Thomas Voit, MD, PhD
Professor Voit is the Director Designate of the Biomedical Research Centre (BRC) at Great Ormond Street Hospital for Children NHS Foundation Trust and the Institute of Child Health, University College London. Professor Voit previously served as the Medical and Scientific Director of the Institute of Myology and Director of an INSERM/CNRS Research Centre at Pierre et Marie Curie Sorbonnes Universities, Paris. Prior to this he was a professor and the Head of Paediatrics at University Hospital, Essen.
Robert “Bob” Brown, Jr., MD, PhD
Dr. Brown is Professor and Chair of Neurology at the University of Massachusetts Medical Center and Medical School, where he also directs the Day Neuromuscular Research Laboratory. He Is a pioneer in understanding the genetic basis of ALS, and led the team that identified the first gene linked to ALS, SOD1, in 1993.